UTHR logo

United Therapeutics (UTHR) EBITDA

annual EBITDA:

$1.65B+$267.60M(+19.30%)
December 31, 2024

Summary

  • As of today (May 30, 2025), UTHR annual EBITDA is $1.65 billion, with the most recent change of +$267.60 million (+19.30%) on December 31, 2024.
  • During the last 3 years, UTHR annual EBITDA has risen by +$992.00 million (+149.76%).
  • UTHR annual EBITDA is now at all-time high.

Performance

UTHR EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherUTHRincome statement metrics

quarterly EBITDA:

$449.40M+$25.30M(+5.97%)
March 31, 2025

Summary

  • As of today (May 30, 2025), UTHR quarterly EBITDA is $449.40 million, with the most recent change of +$25.30 million (+5.97%) on March 31, 2025.
  • Over the past year, UTHR quarterly EBITDA has increased by +$22.50 million (+5.27%).
  • UTHR quarterly EBITDA is now -39.75% below its all-time high of $745.90 million, reached on September 30, 2015.

Performance

UTHR quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherUTHRincome statement metrics

TTM EBITDA:

$1.68B+$22.50M(+1.36%)
March 31, 2025

Summary

  • As of today (May 30, 2025), UTHR TTM EBITDA is $1.68 billion, with the most recent change of +$22.50 million (+1.36%) on March 31, 2025.
  • Over the past year, UTHR TTM EBITDA has increased by +$182.20 million (+12.19%).
  • UTHR TTM EBITDA is now at all-time high.

Performance

UTHR TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherUTHRincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

UTHR EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+19.3%+5.3%+12.2%
3 y3 years+149.8%+37.9%+78.6%
5 y5 years+2308.8%+133.8%+124.4%

UTHR EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+149.8%at high+165.1%at high+91.7%
5 y5-yearat high+2308.8%at high+806.0%at high+194.3%
alltimeall timeat high+2127.9%-39.8%+171.3%at high+1291.0%

UTHR EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-
$449.40M(+6.0%)
$1.68B(+1.4%)
Dec 2024
$1.65B(+19.3%)
$424.10M(+1.5%)
$1.65B(+6.4%)
Sep 2024
-
$417.80M(+8.4%)
$1.55B(+2.4%)
Jun 2024
-
$385.60M(-9.7%)
$1.52B(+1.5%)
Mar 2024
-
$426.90M(+31.7%)
$1.49B(+7.8%)
Dec 2023
$1.39B(+34.1%)
$324.20M(-14.8%)
$1.39B(+9.5%)
Sep 2023
-
$380.70M(+4.9%)
$1.27B(+3.8%)
Jun 2023
-
$362.90M(+13.8%)
$1.22B(+18.8%)
Mar 2023
-
$319.00M(+56.1%)
$1.03B(-0.7%)
Dec 2022
$1.03B(+56.1%)
$204.30M(-38.9%)
$1.03B(+4.7%)
Sep 2022
-
$334.60M(+97.4%)
$987.80M(+12.9%)
Jun 2022
-
$169.50M(-48.0%)
$874.60M(-6.8%)
Mar 2022
-
$325.90M(+106.5%)
$938.70M(+41.7%)
Dec 2021
$662.40M(-7.0%)
$157.80M(-28.7%)
$662.40M(+4.0%)
Sep 2021
-
$221.40M(-5.2%)
$636.90M(-2.2%)
Jun 2021
-
$233.60M(+371.0%)
$651.20M(+14.3%)
Mar 2021
-
$49.60M(-62.5%)
$569.70M(-20.0%)
Dec 2020
$712.30M(-1051.0%)
$132.30M(-43.9%)
$712.30M(+6.2%)
Sep 2020
-
$235.70M(+55.0%)
$670.80M(+7.1%)
Jun 2020
-
$152.10M(-20.9%)
$626.40M(-16.2%)
Mar 2020
-
$192.20M(+111.7%)
$747.30M(-1097.7%)
Dec 2019
-$74.90M(-109.3%)
$90.80M(-52.5%)
-$74.90M(+26.9%)
Sep 2019
-
$191.30M(-29.9%)
-$59.00M(-39.0%)
Jun 2019
-
$273.00M(-143.3%)
-$96.70M(-31.3%)
Mar 2019
-
-$630.00M(-690.4%)
-$140.80M(-117.4%)
Dec 2018
$808.70M(-0.1%)
$106.70M(-30.5%)
$808.70M(-5.3%)
Sep 2018
-
$153.60M(-32.9%)
$854.20M(-17.3%)
Jun 2018
-
$228.90M(-28.4%)
$1.03B(+20.5%)
Mar 2018
-
$319.50M(+109.9%)
$856.70M(+5.8%)
Dec 2017
$809.50M(-26.1%)
$152.20M(-54.1%)
$809.50M(-3.5%)
Sep 2017
-
$331.70M(+522.3%)
$838.80M(+11.1%)
Jun 2017
-
$53.30M(-80.4%)
$754.90M(-24.2%)
Mar 2017
-
$272.30M(+50.0%)
$995.80M(-9.1%)
Dec 2016
$1.10B(+1.3%)
$181.50M(-26.8%)
$1.10B(+1.6%)
Sep 2016
-
$247.80M(-15.8%)
$1.08B(-31.6%)
Jun 2016
-
$294.20M(-21.0%)
$1.58B(+7.9%)
Mar 2016
-
$372.20M(+126.4%)
$1.46B(+35.0%)
Dec 2015
$1.08B(+88.2%)
$164.40M(-78.0%)
$1.08B(-2.1%)
Sep 2015
-
$745.90M(+318.8%)
$1.10B(+228.9%)
Jun 2015
-
$178.10M(-2882.8%)
$335.89M(-2.1%)
Mar 2015
-
-$6.40M(-103.4%)
$343.21M(-40.3%)
Dec 2014
$575.00M(+75.2%)
$187.21M(-913.3%)
$575.00M(+56.0%)
Sep 2014
-
-$23.02M(-112.4%)
$368.48M(-27.0%)
Jun 2014
-
$185.42M(-17.7%)
$504.88M(+12.2%)
Mar 2014
-
$225.39M(-1266.9%)
$450.18M(+37.2%)
Dec 2013
$328.22M(-32.2%)
-$19.32M(-117.0%)
$328.22M(-32.2%)
Sep 2013
-
$113.38M(-13.3%)
$484.27M(-1.3%)
Jun 2013
-
$130.72M(+26.4%)
$490.68M(+3.6%)
Mar 2013
-
$103.44M(-24.4%)
$473.42M(-2.3%)
Dec 2012
$484.45M(+42.1%)
$136.73M(+14.1%)
$484.45M(+16.0%)
Sep 2012
-
$119.79M(+5.6%)
$417.72M(+2.7%)
Jun 2012
-
$113.46M(-0.9%)
$406.59M(-1.6%)
Mar 2012
-
$114.47M(+63.5%)
$413.01M(+20.8%)
DateAnnualQuarterlyTTM
Dec 2011
$341.02M(+76.9%)
$70.00M(-35.6%)
$341.83M(+17.1%)
Sep 2011
-
$108.66M(-9.4%)
$291.81M(+16.1%)
Jun 2011
-
$119.88M(+177.0%)
$251.33M(+26.9%)
Mar 2011
-
$43.28M(+116.6%)
$198.10M(+2.8%)
Dec 2010
$192.78M(+348.0%)
$19.98M(-70.7%)
$192.76M(+9.3%)
Sep 2010
-
$68.18M(+2.3%)
$176.42M(+43.3%)
Jun 2010
-
$66.65M(+75.7%)
$123.12M(+117.6%)
Mar 2010
-
$37.94M(+940.3%)
$56.58M(+31.5%)
Dec 2009
$43.04M(-163.5%)
$3.65M(-75.5%)
$43.03M(-146.8%)
Sep 2009
-
$14.88M(>+9900.0%)
-$91.91M(+8.2%)
Jun 2009
-
$108.00K(-99.6%)
-$84.91M(+28.6%)
Mar 2009
-
$24.40M(-118.6%)
-$66.03M(-11.3%)
Dec 2008
-$67.75M(-405.4%)
-$131.30M(-700.0%)
-$74.44M(-214.6%)
Sep 2008
-
$21.88M(+15.2%)
$64.98M(+13.5%)
Jun 2008
-
$18.99M(+18.8%)
$57.26M(+22.9%)
Mar 2008
-
$15.98M(+96.7%)
$46.57M(+100.3%)
Dec 2007
$22.18M(-27.1%)
$8.13M(-42.6%)
$23.25M(+24.4%)
Sep 2007
-
$14.16M(+70.5%)
$18.70M(+14.2%)
Jun 2007
-
$8.30M(-213.2%)
$16.38M(-18.5%)
Mar 2007
-
-$7.33M(-305.3%)
$20.09M(-34.0%)
Dec 2006
$30.45M(-32.8%)
$3.57M(-69.8%)
$30.45M(-19.6%)
Sep 2006
-
$11.83M(-1.5%)
$37.85M(-8.0%)
Jun 2006
-
$12.02M(+297.8%)
$41.14M(+0.6%)
Mar 2006
-
$3.02M(-72.5%)
$40.90M(-9.7%)
Dec 2005
$45.31M(+192.6%)
$10.97M(-27.5%)
$45.31M(+9.8%)
Sep 2005
-
$15.13M(+28.4%)
$41.26M(+27.3%)
Jun 2005
-
$11.78M(+58.5%)
$32.41M(+31.2%)
Mar 2005
-
$7.43M(+7.2%)
$24.70M(+59.5%)
Dec 2004
$15.48M(-268.3%)
$6.93M(+10.4%)
$15.49M(+172.9%)
Sep 2004
-
$6.27M(+54.1%)
$5.67M(-419.8%)
Jun 2004
-
$4.07M(-327.6%)
-$1.77M(-78.0%)
Mar 2004
-
-$1.79M(-37.9%)
-$8.08M(-12.2%)
Dec 2003
-$9.20M(-38.1%)
-$2.88M(+145.6%)
-$9.20M(+2.9%)
Sep 2003
-
-$1.17M(-47.4%)
-$8.94M(-34.9%)
Jun 2003
-
-$2.23M(-23.5%)
-$13.74M(+16.1%)
Mar 2003
-
-$2.91M(+11.1%)
-$11.83M(-20.4%)
Dec 2002
-$14.87M(-65.8%)
-$2.62M(-56.1%)
-$14.87M(-27.0%)
Sep 2002
-
-$5.97M(+1736.9%)
-$20.36M(-20.0%)
Jun 2002
-
-$325.00K(-94.5%)
-$25.45M(-31.9%)
Mar 2002
-
-$5.95M(-26.6%)
-$37.34M(-12.4%)
Dec 2001
-$43.42M(-46.8%)
-$8.11M(-26.6%)
-$42.62M(-35.0%)
Sep 2001
-
-$11.06M(-9.5%)
-$65.58M(+1.0%)
Jun 2001
-
-$12.22M(+8.8%)
-$64.93M(-22.0%)
Mar 2001
-
-$11.23M(-63.9%)
-$83.20M(+2.0%)
Dec 2000
-$81.58M(+122.5%)
-$31.07M(+198.5%)
-$81.58M(+32.9%)
Sep 2000
-
-$10.41M(-65.8%)
-$61.37M(+6.1%)
Jun 2000
-
-$30.48M(+217.1%)
-$57.86M(+72.3%)
Mar 2000
-
-$9.61M(-11.5%)
-$33.58M(-7.4%)
Dec 1999
-$36.66M(+174.7%)
-$10.86M(+57.4%)
-$36.26M(+42.8%)
Sep 1999
-
-$6.90M(+11.3%)
-$25.40M(+37.3%)
Jun 1999
-
-$6.20M(-49.6%)
-$18.50M(+50.4%)
Mar 1999
-
-$12.30M
-$12.30M
Dec 1998
-$13.35M
-
-

FAQ

  • What is United Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for United Therapeutics?
  • What is United Therapeutics annual EBITDA year-on-year change?
  • What is United Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for United Therapeutics?
  • What is United Therapeutics quarterly EBITDA year-on-year change?
  • What is United Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for United Therapeutics?
  • What is United Therapeutics TTM EBITDA year-on-year change?

What is United Therapeutics annual EBITDA?

The current annual EBITDA of UTHR is $1.65B

What is the all time high annual EBITDA for United Therapeutics?

United Therapeutics all-time high annual EBITDA is $1.65B

What is United Therapeutics annual EBITDA year-on-year change?

Over the past year, UTHR annual EBITDA has changed by +$267.60M (+19.30%)

What is United Therapeutics quarterly EBITDA?

The current quarterly EBITDA of UTHR is $449.40M

What is the all time high quarterly EBITDA for United Therapeutics?

United Therapeutics all-time high quarterly EBITDA is $745.90M

What is United Therapeutics quarterly EBITDA year-on-year change?

Over the past year, UTHR quarterly EBITDA has changed by +$22.50M (+5.27%)

What is United Therapeutics TTM EBITDA?

The current TTM EBITDA of UTHR is $1.68B

What is the all time high TTM EBITDA for United Therapeutics?

United Therapeutics all-time high TTM EBITDA is $1.68B

What is United Therapeutics TTM EBITDA year-on-year change?

Over the past year, UTHR TTM EBITDA has changed by +$182.20M (+12.19%)
On this page